Valuation: Interpace Biosciences, Inc.

Market Cap 3.88Cr 3.46Cr 3.19Cr 2.89Cr 5.48Cr 363.62Cr 5.62Cr 38Cr 15Cr 194.67Cr 15Cr 14Cr 613.13Cr P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 3.75Cr 3.34Cr 3.08Cr 2.79Cr 5.29Cr 351.23Cr 5.43Cr 37Cr 15Cr 188.04Cr 14Cr 14Cr 592.24Cr EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 week+28.62%
Current month+25.17%
1 month+16.67%
3 months-13.04%
6 months-28.21%
Current year+13.80%
1 week 5.45
Extreme 5.452
7.45
1 month 4.95
Extreme 4.95
7.45
Current year 4.95
Extreme 4.95
12
1 year 4.03
Extreme 4.0275
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
45
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

13,85,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+28.62%+38.61%+16.67% 3.88Cr
+1.67%-3.68%+7.93%+27.73% 11TCr
+2.00%+7.94%+5.93%+121.87% 10TCr
+3.13%-15.45%+60.54%+605.86% 4.5TCr
+1.18%+8.03%+10.16%+105.72% 3.3TCr
+1.43%+4.57%+47.13%+82.02% 2.98TCr
+1.58%+3.53%+44.66%+97.26% 2.81TCr
+2.00%+7.48%+40.80%+448.80% 2.25TCr
-0.37%+1.18%-17.81%-16.07% 2TCr
-0.91%-1.42%-6.93%+29.88% 1.68TCr
Average +1.20%+3.43%+23.10%+151.98% 4TCr
Weighted average by Cap. +1.67%+0.84%+18.80%+152.30%

Financials

2024 2025
Net sales 4.69Cr 4.19Cr 3.85Cr 3.5Cr 6.63Cr 439.85Cr 6.79Cr 46Cr 18Cr 235.48Cr 18Cr 17Cr 741.67Cr 3.87Cr 3.46Cr 3.18Cr 2.89Cr 5.47Cr 363.01Cr 5.61Cr 38Cr 15Cr 194.34Cr 15Cr 14Cr 612.1Cr
Net income 67.02L 59.82L 55.05L 49.96L 94.68L 63Cr 97.03L 6.59Cr 2.62Cr 34Cr 2.52Cr 2.46Cr 105.93Cr 2.46Cr 2.19Cr 2.02Cr 1.83Cr 3.47Cr 230.35Cr 3.56Cr 24Cr 9.62Cr 123.32Cr 9.22Cr 9.03Cr 388.41Cr
Net Debt 43.95L 39.23L 36.1L 32.76L 62.09L 41Cr 63.63L 4.32Cr 1.72Cr 22Cr 1.65Cr 1.61Cr 69Cr -13.22L -11.8L -10.86L -10L -18.68L -12Cr -19.14L -1.3Cr -51.77L -6.63Cr -49.62L -48.56L -21Cr
Projected Income Statement - Annual - Interpace Biosciences, Inc.
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
06/26/06 $7.000 0.00% 305
05/26/05 $7.000 +22.38% 2,110
04/26/04 $5.720 +5.10% 2,462

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Interpace Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IDXG Stock